Instrument Grant Program Recipients
Congratulations
to all of our grant recipients. We look forward to receiving your application
and adding your name to this list of grantees.
Microplate Luminometer My lab is interested in how outside signals such as hormones and growth factors are interpreted in the cellular signaling network. We use a variety of high-throughput experimental methods to gather information about multiple signaling pathways and perform computational analysis to identify new drug targets. We use the Veritas Microplate Luminometer with Dual Injectors for many of our experimental assays due to the sensitivity of luminescent assays combined with the high-throughput design. In particular, we rely on reporter gene assays to determine the activity of transcription factors, luminescent assays for kinase activity and cAMP levels to monitor signaling activity, and a variety of luminescent assays to characterize cell behaviors such as apoptosis and proliferation. Microplate Multimode Reader set up as a Luminometer I am the Director of my university’s Molecular Biology Core Facility (MBCF), a multi-user facility dedicated to advancing molecular biology-based research and education for all interested students and personnel. The MBCF accomplishes this mission by 1) providing access to, and training in, the theory and use of instrumentation not affordable by smaller laboratories; 2) providing consultation services and technical assistance to educators and researchers; 3) performing analyses on a fee-for-service basis; and 4) offering a variety of educational experiences including classroom demonstrations, student research rotations and hands-on intensive workshops. Since the MBCF is the ONLY facility of its kind within a 90 mile radius all faculty, staff, and students (undergraduate, graduate, or medical) interested in biotechnology utilize the programs offered by the MBCF either directly or indirectly (e.g., a faculty member receiving training and bringing it to their laboratory). Further, while the MBCF was clearly developed to serve the needs of the East Tennessee State University community, it routinely hosts faculty and students from nearby colleges so that they may have access to technology not available to them otherwise. Microplate Multimode Reader set up as a Luminometer
Tanja Stoyan, Ph.D. Coordinator Undergraduate Teaching Laboratory I coordinate and teach laboratory classes for undergraduates in pharmacology and immunology. Approximately 60 students graduate from these classes each year with a B.S. in Pharmacology or a B.S. in Microbiology/Cell Biology. These are classes for seniors and many of our students go on to work in the Biotech and Pharmaceutical Industries after they graduate. We are intending to expose our students to a wide variey of biochemical techniques that apply to molecular pharmacology. Recently we have developed new exercises for our classes using Flow Cytometry. My goal is to introduce our Pharmacology and Immunology students to the field of Luminometry and to develop several exercises that use this powerful technique. I will give you a brief overview about the Pharmacology program. The lab courses require pharmacology majors to spend one day each week for two quarters performing experiments to demonstrate the site and mechanism of action of a wide variety of drugs and chemical agents using different in vitro isolated tissue preparations, as well as in vivo, using anesthetized mice and rabbits. The winter quarter lab is designed to teach common biochemical techniques that are routinely used to investigate site and mechanism of action of drugs. The series of laboratory exercises include an ELISA assay to determine the concentration of protein in a sample, a radioactive drug-receptor-binding filter assay, a pharmacokinetic study to identify metabolites following different routes of administration of a therapeutic agent, isolation of liver microsomes for drug metabolism study, including identification of p450 enzymes by gel electrophoresis and immuno-blot, the amplification of G protein cDNA using PCR and a new Flow Cytometry exercise to determine the EC50 of drugs on apoptotic Jurkat cells. In addition to the experiments described above the students are required to complete a 3-dimensional molecular modeling computer exercise teaching them how to interpret structure-activity relationship of drugs and molecular binding at drug-receptor sites. The students use various software packages to analyze their data (Excel, Sigmaplot, Flow Cytometry software). Our goal is to keep the class up to date with new technologies and instrumentation. We feel that luminometry is a very important research tool. We will be using Cell Viability and Apoptosis assays, Cell titer glo, Caspase-Glo, High Through put compound screening: p450 glo, kinase-glo plus assay, pGL4, luciferase reporter vectors, Dual-glo luciferase assay system. One assay that we are interested in developing is an assay to screen for GPRC modulators which is described in Cell Notes, Issue 16, 2006 from Promega. We would introduce a luciferase reporter plasmid into various cell lines and have the students add drugs from an 80 compound library to the cells (alternatively a series of dilutions of one single drug). We would then assay for firefly and Renilla luciferase activity using the Dual-glo assay system. The results would be measured in a 96 microplate luminometer. Another application would be to assay apoptotic activity of drugs in our compound library on Jurkat cells with a luminescent assay. A high throughput screen using Flow cytometry has been difficult to do in the class format since the time for reading the 96 well plate is too long. (2008) 96-well Luminometer (Granted once per year in December) Valerie Hu Personalized Diagnosis and Treatment
of Autism Spectrum Disorders
(2006) 96-well Luminometer (Granted once per year in December) (2005) 96-well Luminometer (2004) 96-well Luminometer
(2008) Single Tube Multimode
Reader set up as a Luminometer (2008) Single Tube
Multimode Reader set up as a Luminometer I am an assistant tenure track biology professor at the University of
South Carolina. I am pursuing both basic and translational research in my
laboratory. My basic research focuses on the role of HOX gens in breast
cancer development. HOX genes encode a large family of transcriptional
regulatory proteins containing a conserved DNA binding domain called
homeodomain. Homeodomain-containing proteins determine the phenotypic
outcome of a variety of embryonic cells by ensuring that specifically
timed differentiation programs are set in place in these cells. In recent
years, a large body of literature has been generated about the abnormal
expression of HOX genes in a variety of tumors. However, very little is
known about how abnormal expression of HOX genes can lead to tumor
formation. Our previous studies have shown that HOXA5 acts as a tumor
suppressor gene, on the other hand, HOXB7 acts as an oncogene. As a
classical transcription factor, we hypothesize that HOXA5 and HOXB7 exert
their functions by directly or indirectly regulating the expression of
their target genes. Microarray and western blot analysis have identified
many potential target genes of HOXA5 and HOXB7 (Chen et al. 2005. Single Tube
Multimode Reader set up as a Luminometer
Single Tube Multimode Reader set up
as a Luminometer
Single Tube Multimode Reader set
up as a Luminometer Dr. Raju C. Reddy is an Assistant Professor of Internal Medicine in the Division of Pulmonary and Critical Care Medicine at the University of Michigan School of Medicine. He was granted a Modulus Luminometer to study the role of the nuclear hormone receptor, peroxisome proliferator-activated receptor-gamma (PPAR-gamma), in lung tumorigenesis, pulmonary fibroproliferative responses, and alveolar macrophage function. Further characterizing the functional significance of PPAR-gamma in pulmonary (patho)biology will potentially result in the identification of novel therapeutic targets.
Research Goals = Further Characterization of Interferon Responsive Factor 2 Binding Protein 1 as a novel cardiac-enriched transcription cofactor that coactivates the vascular endothelial growth factor promoter. My laboratory is broadly interested in the regulation of neurotransmitters and growth factors. This year, a student in my laboratory (Matthew G. Crowson) is studying the mechanism of vascular endothelial growth factor (VEGF) promoter regulation following hypoxia by RTEF-1, a member of the TEA domain family of transcription factors. Specifically Matt has investigated Vestigial-like 4 (VGLL4), a cardiac-enriched transcription cofactor, and its interaction with the TEAD factors, including TEF-1 and RTEF-1 along with colleagues from the University of Ottawa Heart Institute. In previous studies, VGLL4 was used as bait to screen a mouse cardiac cDNA library in a yeast two-hybrid screen. The two-hybrid screen identified Interferon responsive factor 2 (IRF2) and interferon responsive factor 2 binding protein 2 (IRF2BP2) as a specific cofactors of VGLL4. Whereas IRF2 mRNA was not detected in normal tissues, Northern blot analysis showed that IRF2BP2 mRNA is enriched in cardiac and skeletal muscles. The IRF2BP2 and VGLL4 interaction was confirmed and further characterized by a mammalian two-hybrid assay in the myogenic C2C12 cell line. In addition, specific two conserved TEF-1-interacting TDU motifs in VGLL4 were identified as necessary for IRF2BP2/VGLL4 interaction since deletion of both motifs abolished and removal of one or the other motif reduced the protein-protein interaction. Single Tube Luminometer
Ravi Prakash Sahu, PhD Single Tube Luminometer Single Tube Luminometer Single Tube Luminometer Single Tube Luminometer Masahiro Sakagami Assistant Professor Virginia Commonwealth University Pharamceutics, School of Pharmacy Richmond, Virginia http://www.pubinfo.vcu.edu/pharmacy/Faculty/FacDetail.asp?ID=85 The goals of my research program are to facilitate our understandings of lung biopharmaceutics and pharmacology for inhaled therapeutics and those of lung (patho)physiology under various diseases. Specifically, the current research project requiring the use of the 20/20n luminometer concerns pivotal biopharmaceutics issues of various inhaled corticosteroids (ICSs) treating asthmatic lungs. It has been shown that therapeutic efficacy of ICSs is not solely defined by their intrinsic anti-inflammatory potencies, such as glucocorticosteroid receptor binding affinity. It is hypothesized that local lung kinetics of aerosol deposition, dissolution and cellular uptake is also involved. Nevertheless, for their in vitro anti-inflammatory action assessments, conventional methods have employed non-confluent lung epithelial cells that are transiently transfected with inflammation-related genes (e.g., NFkB or AP1), which disregard such local lung cellular kinetics of ICS disposition. In this sense, we have recently developed a transfection protocol that enables the maintenance of sufficiently high levels of inflammation-related genes, even after the formation of tightly-packed, confluent lung epithelial cell (Calu-3) monolayers. Notably, these monolayers are capable of being grown under the air-interface culture, a culture fed only by basolateral medium, so that their semi-dry apical (mucosal) surfaces would allow direct aerosol deposition of ICSs into a limited volume of the cell lining fluid. This will give us a unique opportunity to assess trans-repression kinetics (e.g., onsets and potencies) of various ICSs upon their aerosol deposition and dissolution on the Calu-3 monolayer surfaces, using a reporter gene assay based on luciferase activity. Successful completion of this project will facilitate our understandings of ICS pharmacology and kinetics in lung. It is also believed that this unique and novel in vitro system is capable of leading to the discovery of novel therapeutic entities that exhibit anti-inflammatory actions for the treatment of a variety of other lung diseases via inhalation, by testing different classes of entities. It should be noted that this system is also capable of evaluating inflammatory responses and barrier function alterations of lung epithelium in response to inhalation aerosol deposition of more general substances, such as cigarette smokes and environment pollutants. List of Assays = Luciferase activity from transient transfection of a reporter plasmid construct of inflammation-related transcription factor, pNFkB-Luc or pAP1-Luc, will be assayed with the cell lysates prepared from the Calu-3 monolayers following aerosol deposition and subsequent air-interface culture of various ICSs, such as fluticasone propionate, mometasone furoate, flunisolide, budesonide, triamcinolone acetonide and beclomethasone dipropionate. Preliminary transfection results obtained using a 20/20n luminometer owned by the School of Medicine at our University successfully induced the luciferase activity to 7.73±0.96 x 104 RLU (n=10) maintained in the tightly-packed confluent Calu-3 monolayers. Most importantly, one of the least soluble ICSs, fluticasone propionate, at 0.4 mM has shown to suppress such an induced activity following 24 hr incubation under the air-interface culture. All of these results should be quite convincing for a likely success of this project, given an award of own 20/20n luminometer in our laboratory for non-interrupted access for efficient progress and productivity in this research. Description of Application = In this project, Calu-3 will be grown under the air-interface culture in the Transwell and transiently transfected with pNFkB-Luc or pAP1-Luc on Day 8 with an assist by a chelating agent, 2.5 mM ethyleneglycotetraacetic acid (EGTA). This protocol has been shown by us that efficient gene construct uptake and maintenance of high level transfection were feasible even after the formation of tightly-packed, confluent Calu-3 monolayers. On Day 12, the transfected Calu-3 monolayers will be subjected to aerosol deposition of various ICSs on their mucosal surface at different doses and sizes using the Andersen cascade impactor (ACI), a pharmacopeial testing instrument for particle size measurement of inhaler products. Briefly, each of the ICSs will be aerosolized from commercial inhalers and introduced into ACI, in which the semi-dry, confluent and transfected Calu-3 monolayers in the Transwell inserts will deposit the ICS aerosols by impaction. This unique system has been shown to enable accurate <0.2 mg of ICS deposition onto the 4.5 cm2 cell surfaces. Following continuing air-interface culture for various periods, the cell lysates will be prepared, according to the protocol given by Promega (Madison, WI), and their luciferase activity will be determined by an awarded 20/20n luminometer. This will enable characterization of trans-repression onsets and potencies for each of the ICSs at each dose and aerosol size deposition. Such trans-repression kinetics should be quite different from those reported from conventional in vitro methods using non-confluent cells and their ICS exposure under fully submerged incubation, by virtue of formidable barrier formation restricting ICS uptake into the cells and aerosol deposition and dissolution kinetics on the semi-dry Calu-3 surfaces with a limited volume of the cell lining fluid taken into account in the proposed studies. Obviously, our assessment with aerosol application should be a closer representation of real ICS actions in the organ following inhalation. Single Tube Luminometer Justin Hanes, Associate Professor Johns Hopkins University Chemical & Biomolecular Engineering Department Baltimore, Maryland http://www.jhu.edu/~cheme/hanes/ The primary goal of our lab is to design synthetic, non-viral gene carriers that can overcome various biological barriers and efficiently deliver therapeutic genes. Gene therapy represents a promising strategy to combat diseases ranging from single gene defects to cancers, and many gene targets have been established. However, the development of safe and effective delivery strategies is widely recognized as the Achilles’ heel of gene therapy, due to the numerous extracellular and intracellular barriers. Our group is unique in our strategy to combine high resolution video microscopy and cellular biology to elucidate the dynamic behavior of gene carriers in complex biological environments. The improved understanding can in turn facilitate the rational development of new generations of gene carriers. This approach is recently validated by the 1000-fold improvement in gene carrier transport across the highly viscoelastic mucus barrier, as well as the potential exploitation of a novel endocytic pathway and intracellular trafficking that minimizes gene degradation in cells. Our work in this area has been featured in over 30 scientific journals/news, including Nature Biotechnology and Journal of American Medical Association (JAMA) We are actively designing new generations of gene carriers for several formidable diseases, including cystic fibrosis (CF) as well as malignant cancers of the lung, ovary and liver. List of Assays = (i) In vitro / in vivo transfection assay, (ii) siRNA knockdown study, (iii) promoter activity assay The luminometer will be used as a broad platform to evaluate the gene transfer efficiency of our new generations of gene carrier. gWiz luciferase plasmid (Aldevron) will be condensed into small nanoparticles with different surface and biologically-active functionalities. The efficacy of the gene carriers will be evaluated in vitro and in vivo using the Dual Luciferase Reporter Assay (Promega). One example is to study the efficiency of gene carriers administered to mucus covered lung epithelial cells for cystic fibrosis, where the thick mucus layer is a formidable barrier for gene therapy. The luciferase assay represents an important complementary tool to our current green fluorescence protein (GFP) based reporter protein, because it allows us to standardize our results to the luciferase assay commonly used in the field, and facilitate much higher throughput of in vivo testing due to auto-fluorescence in animals. The ease of the luciferase assay will greatly aid our development of new generations of efficient gene carriers. As an alternative to gene therapy, we are also researching on the development of therapies in cancer cells based on RNA-silencing (siRNA) technology. In collaboration with the Department of Gynecology and School of Public Health, we develop new polymeric carriers that can achieve targeted delivery of siRNA to ovarian and lung cancer cells. The luminometer allows us to rapidly measure the efficiency of siRNA delivery by measuring the luciferase knockdown in cells and mice stably transfected with a constitutively expressing luciferase vector. Another goal in our laboratory is to study the effects of specific promoters on expression profiles of therapeutic genes. For example, it is known that certain promoters have higher activity in specific types of cancers. This affords further improvement in the expression of genes in targeted cells. The luciferase assay represents a high-throughput platform for us to scan for optimal promoters in a variety of cell lines. Single Tube Luminometer Single Tube Luminometer William Baldwin, Associate Professor Clemson University Clemson Institute of Environmental Toxicology Pendleton, South Carolina http://www.clemson.edu/entox/index.htm It is estimated that 106,000 people die each year from adverse drug reactions. Many of these drug reactions are caused by concomitant exposure to other drugs, alternative medicines, pesticides, contraindicated foods. Our goal is to identify and determine the potential for a number of xenobiotics such as pharmaceuticals, pesticides, nutraceuticals, and alternative medicines to cause drug-drug or toxicant-drug interactions by inducing P450 enzymes. Identification of the chemicals that induce P450s will help us predict adverse drug interactions and save lives. List of Assays = Dual-Glo luciferase, Steady Glo luciferase, P450-Glo CYP3A4, 1A1, 1A2, 2C8, 2C9, 2C19, and to a lesser extent 3A7 and 2D6. We investigate the potential for drug-drug interactions by determining the (1) toxicants and alternative medicines that activate the constitutive androstane receptor (CAR) or the pregnane X-receptor (PXR), (2) determining the P450s induced in cell systems and in wild-type (CAR/PXR +/+), CAR-null, PXR-null, and mice humanized for CAR and PXR, and (3) determining whether there are sexually dimorphic differences in P450 induction. CAR and PXR are xenosensing nuclear receptors that recognize high concentrations of foreign chemicals and some endobiotics in our bodies and in turn induce drug metabolizing enzymes such as the P450s. We will perform in vitro screening assays (about 48 luciferase assays per week) to determine chemicals that may activate these nuclear receptors, and then follow-up with dose-response curves. Chemicals that activate at concentrations of concern will then be provided to colonies of wild-type and nuclear receptor null mice to determine if these chemicals have the potential to activate CAR or PXR in vivo. Further studies will be performed in humanized mice or human primary cells to determine the relevance of our data to human health. Real-time quantitative PCR, Western blots, and P450-Glo assays will be used to determine the P450s induced, or in some cases the P450s inhibited by the toxicant of interest. Single Tube Luminometer Xiongbin Lu, Assistant ProfessorUniversity of South Carolina Biologial Sciences Department Columbia, South Carolina In my laboratory, we are interested in the p53 tumor suppressor and its signaling pathways. p53 activity is tightly controlled in the cell. To elucidate how p53 is regulated, we will measure its activity by luciferase assays. We will transfect cells with luciferase expression vectors driven by the promoters of p53-targeting genes such as p21, Mdm2 and Bax promoters. P53 transcriptional activity will be determined by measuring luciferase activity in each cell sample. Turner 20/20n luminometer will greatly facilitate our research and provides a precise way for us to clarify the mechanisms by which p53 is activated or suppressed. Single
Tube Luminometer Single Tube Luminometer Dr. Dennis De Luca is an associate professor at Ohio Northern University. The Department of Biological and Allied Health Sciences has 18 full-time professors with nearly 300 majors. The students major in Clinical Laboratory Sciences, environmental studies, molecular biology, forensic biology and as preprofessional biology majors. The basic science departments serve the needs of the largest pharmacy program (Pharm.D.)in the state of Ohio. The courses in molecular, cell, microbiology, toxicology, genetics will be enhanced using assays for DNA quantitation, reporter gene systems,and other luminescence assays with the use of this luminometer.
Single Tube Luminometer Dr. William Kim is an Assistant Professor at Columbia University Medical Center in New York, NY. He was granted a 20/20n luminometer that will help to measure subcellular localization of luminescent potential target marker construct molecules in transfected cells. Their research is focused on studying the molecular and cellular mechanisms of diabetes and cardiovascular diseases.
Single Tube Luminometer
Single Tube Luminometer
Single Tube Luminometer
Single Tube Microplate
Luminometer Single Tube Microplate
Luminometer Single Tube Microplate
Luminometer
|
|
|
Promega Corporation |
|
|
|